A biomarker for severity of Alzheimer’s disease: ¹H-NMR resonances in cerebrospinal fluid correlate with performance in mini-mental-state-exam

References

• Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Münch G. (2005). Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. J Neurochem 92:255–263.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. (2009). Cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis 18:413–417.
   PubMed Web of Science ®Google Scholar
• Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. (2007). Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68:1809–1814.
   PubMed Web of Science ®Google Scholar
• Busse A, Aurich C, Zaudig M, Riedel-Heller S, Matschinger H, Angermeyer MC. (2002). [Age- and education-specific reference values for the cognitive test of the SIDAM (Structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other etiology according to ICD-10 and DSM-IV)]. Z Gerontol Geriatr 35:565–574.
   Google Scholar
• Dubois B, Slachevsky A, Litvan I, Pillon B. (2000). The FAB: a Frontal Assessment Battery at bedside. Neurology 55:1621–1626.
   PubMed Web of Science ®Google Scholar
• Essig M, Schoenberg SO. (2003). [Radiologic diagnostics of dementia]. Radiologe 43:531–536.
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198.
   PubMed Web of Science ®Google Scholar
• Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group. (2009). Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med 361:245–254.
   PubMed Web of Science ®Google Scholar
• Grober E, Merling A, Heimlich T, Lipton RB. (1997). Free and cued selective reminding and selective reminding in the elderly. J Clin Exp Neuropsychol 19:643–654.
   PubMed Web of Science ®Google Scholar
• Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, Herholz K, Heiss WD, Hampel H. (2008). CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer’s disease. Eur J Neurol 15:1155–1162.
   Google Scholar
• Hansson SF, Andréasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K. (2009). Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzheimers Dis 16:389–397.
   PubMed Web of Science ®Google Scholar
• Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. (2000). Wechsler Gedächtnistest-Revidierte Fassung (WMS-R), Testmanual, deutsche Adaptation der revidierten Fassung der Wechsler Memory Scale von David Wechsler. Bern: Hans Huber.
   Google Scholar
• Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H. (1998). The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 9 Suppl 2:20–26.
   PubMed Web of Science ®Google Scholar
• Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, Silverberg GD, Möller HJ, Yesavage JA, Tinklenberg JR, Shooter EM, Murphy GM Jr. (2000). Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology 54:1498–1504.
   PubMed Web of Science ®Google Scholar
• Kantarci K, Jack CR Jr. (2003). Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin n Am 13:197–209.
   PubMed Web of Science ®Google Scholar
• Kork F, Holthues J, Hellweg R, Jankowski V, Tepel M, Ohring R, Heuser I, Bierbrauer J, Peters O, Schlattmann P, Zidek W, Jankowski J. (2009). A possible new diagnostic biomarker in early diagnosis of Alzheimer’s disease. Curr Alzheimer Res 6:519–524.
   Google Scholar
• Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, Gao F, Ohlendorf M, Ladenson JH. (2008). The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 54:1617–1623.
   Google Scholar
• Leifer BP. (2003). Early diagnosis of Alzheimer’s disease: clinical and economic benefits. J Am Geriatr Soc 51:S281–S288.
   PubMed Web of Science ®Google Scholar
• McGeer EG, McGeer PL. (2003). Clinically tested drugs for Alzheimer’s disease. Expert Opin Investig Drugs 12:1143–1151.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944.
   PubMed Web of Science ®Google Scholar
• Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, van Belle G, Fillenbaum G, Heyman A. (1993). The consortium to establish a registry for Alzheimer’s disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology 43:2457–2465.
   PubMed Web of Science ®Google Scholar
• Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. (1988). Consortium to establish a registry for Alzheimer’s disease (CERAD) clinical and neuropsychological assessment of Alzheimer’s disease. Psychopharmacol Bull 24:641–652.
   PubMed Web of Science ®Google Scholar
• Olson L, Humpel C. (2010). Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer’s disease and mild cognitive impairment. Exp Gerontol 45:41–46.
   PubMed Web of Science ®Google Scholar
• Pluta R. (2007). Role of ischemic blood-brain barrier on amyloid plaques development in Alzheimer’s disease brain. Curr Neurovasc Res 4:121–129.
   Google Scholar
• Prince, M, Jackson J, Ferri CP (2009). Alzheimer s disease international (World Alzheimer Report). Retrieved from http://http://www.alz.co.uk/research/files/WorldAlzheimerReport-ExecutiveSummary.pdf
   Google Scholar
• Reitan RM, Wolfson D. (2004). The Trail Making Test as an initial screening procedure for neuropsychological impairment in older children. Arch Clin Neuropsychol 19:281–288.
   PubMed Web of Science ®Google Scholar
• Relkin N. (2000). Screening and early diagnosis of dementia. Am J Manag Care 6:S1111–8; discussion S1119.
   Google Scholar
• Shulman KI. (2000). Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15:548–561.
   PubMed Web of Science ®Google Scholar
• Stefani A, Sancesario G, Pierantozzi M, Leone G, Galati S, Hainsworth AH, Diomedi M. (2009). CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer’s and mixed dementia. J Neurol Sci 283:109–115.
   Google Scholar
• Tarawneh R, Holtzman DM. (2010). Biomarkers in translational research of Alzheimer’s disease. Neuropharmacology 59:310–322.
   Google Scholar
• Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. (2002). Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging 23:485–508.
   PubMed Web of Science ®Google Scholar
• Zellner M, Veitinger M, Umlauf E. (2009). The role of proteomics in dementia and Alzheimer’s disease. Acta Neuropathol 118:181–195.
   PubMed Web of Science ®Google Scholar